Global Institute Of Stem Cell Therapy And Research
US: +1-800-914-7836 | Mexico: +1 (619) 866-6000 | India: +91-8905483753


Author's Posts

Research (GIOSTAR) Opens New Location in Glenview, Illinois

GIOSTAR Chicago to Offer Cutting-Edge Regenerative Therapy Options for a Variety of Musculoskeletal and Degenerative Conditions

CHICAGOSept. 7, 2018 /PRNewswire/ — The Global Institute of Stem Cell Therapy and Research (GIOSTAR), the pioneer in regenerative medicine and stem cell-based technologies, announced today the opening of its newest location in Glenview, Illinois at 2614 Patriot Boulevard, Unit A. GIOSTAR Chicago is one of the Institute’s first US facilities, with additional global locations in IndiaChinaMexicoThailandBangladeshSouth AfricaWest AfricaAustralia and UAE.

GIOSTAR, headquartered in San Diego, California, is an established leader in the field, offering cutting-edge regenerative therapy options for sports injuries, joint arthritis, and additional degenerative conditions. The Institute’s advanced regenerative medicine techniques and protocols have been extensively researched and developed by GIOSTAR’s leading scientists for 20 years. The facility’s team consists of world-renowned authorities in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy, and clinical research.

“Patients at GIOSTAR Chicago can benefit from and depend on safe, extensively researched regenerative cell-based therapies designed to rejuvenate and improve several musculoskeletal injuries and degenerative conditions,” said Shelly Sood, partner, GIOSTAR Chicago. “GIOSTAR’s approach to stem cell therapy is not ‘one size fits all,’ as often seen in other local clinics. We take pride in providing an evidence-based approach, and tailor specific therapies to the individual patient. I am honored to be part of such a world-renowned organization that strives to provide the highest quality standards in health care.”

GIOSTAR’s highly-credentialed team of medical professionals has conducted several clinical trials and been involved with a number of high-profile consultations, including the first clinical trial approved by the US Food and Drug Administration (FDA) using stem cells to treat spinal cord injuries at the University of California, Irvine (UCI) in conjunction with the Christopher & Dana Reeve Foundation in 2007; discussions with renowned physicist Stephen Hawking regarding the effects of stem cell research on Amyotrophic Lateral Sclerosis (ALS); and treatments of former athletes including retired NFL player Wayne Hawkins.

“When we formed GIOSTAR, led by Dr. Anand Srivastava more than a decade ago, our goal was to change the face of medicine by delivering the most advanced, elite and expensive science to the masses around the globe,” said Deven Patel, GIOSTAR’s CEO, and co-founder. “Regenerative medicine is a highly complex field that requires years and years of extensive ongoing research. Most local centers do not fully grasp the nuances and intricacies of this field. They do not have teams of dedicated research scientists conducting ongoing US-based research to enable their centers to continue providing the most advanced science to their patients. At GIOSTAR, we do. I am so thankful to our Institute’s team of renowned scientists and medical professionals for helping us bring our vision to fruition.”


Related Links

Source :

Organization Aims to Set up Stem Cell Research Facilities Across Entire U.S.


Organization Aims to Set up Stem Cell Research Facilities Across Entire U.S.

Members of the Global Institute of Stem Cell Therapy and Research (GIOSTAR), held a webinar this month, featuring one of the lead scientists in stem cell research and the organization’s Co-Founder Dr. Anand Srivastava, as part of an ongoing effort to spread the word about GIOSTAR’s Pixel for Cure campaign aimed at setting up 50 non-profit stem cell centers across the country. Potential donors are being asked for $3 or more monthly to fund the effort, in exchange for one pixel, and are also offering products like t shirts and cell phone cases for various amounts. Members said they are excited to share the news about what they are doing around the world, and more locally, here in Los Angeles especially in the Black community.

“I have fought my entire career to develop cures for those that cannot be cured, Srivastava said in a statement released to the Sentinel.

“You no longer need to suffer from debilitating diseases.  But it is no longer my fight.  It is now our fight.  It is now our fight to help those that cannot be helped.  To help cure those that cannot be cured.   Pixel For Cure and our non-profit treatment centers in local communities nationwide aim to solve this issue.  Together we can heal those that need us the most.  Together we are stronger and soon, together, we will be happier and healthier.”

“GIOSTARS’s vision is to provide human stem-cell based therapy to aid all those around the world who are suffering from various types of degenerative and genetic diseases such as Parkinson’s, Alzheimer’s, autism, diabetes, heart and blood related diseases, strokes, spinal cord injuries, paralysis, and more,” said medical experts who are part of the organization’s leadership.

The stem cell is the master cell of the body.

“GIOSTAR’s primary focus is to discover and develop treatments for such diseases with advanced stem cell-based therapies and products through its worldwide development of strategically located stem cell research clinics and hospitals. GIOSTAR’s ultimate aim is to continue to maintain its leadership in the field of stem cell science and to develop affordable delivery systems for the global masses unable to afford the usually high cost of the treatment…”

During the webinar, Dr. Srivastava answered questions from the audience about how stem cells get called into action and taming the autoimmune attack. Stem cell treatments, in fact, said GIOSTAR researchers, are developed for a multitude of diseases from Type 1 diabetes to spinal muscular atrophy.

“During my gene therapy and gene cloning research I discovered that you may replace the defective gene in the pancreas [for example], and the idea is how to replace defective gene with correct gene to reverse diabetes,” Dr. Srivastava said during a previous interview.

“That was back in 1999… If you can replace the defective gene with the correct gene, you can cure the disease basically.”

In order to achieve that, lots of infrastructure is needed, he said.

That’s where the Pixel for Cure campaign comes in, said organizers.

“We’re taught that diabetes is incurable, (for instance) and I’ve recently met Dr. Anand Srivastava, who has changed everything,” said Pixel for Cure CEO and spokesperson Scott Kirkpatrick, who lost his mother to type 1 diabetes.

“We all know someone who has diabetes and with your help, we can save them before its too late… Together, with your blessing, we will treat hundreds of thousands of people in the U.S. who can’t afford this.

“It is impossible to do this without you. We need you to buy a pixel for $3 a month, or more if you can, to accomplish this mission. [GIOSTAR] is improving people’s lives so much and rolling back symptoms so much that you can’t help but call it a ‘cure.’  It’s not a ‘cure’ – but on a daily basis patient’s throughout the world praise this science in gratitude.”

For his part, Dr. Anand Srivastava has been associated with leading universities and research institutions of USA.  In affiliation with University of California San Diego Medical School (UCSD), University of California Irvine Medical School (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical School (UCLA), USA has developed several research projects and has an extensive research experience in the field of Stem cell which is documented by several publications in revered scientific journals.

“Dr. Anand Srivastava’s success has its root in his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cells, tissue targeting, gene therapy and clinical research,” according to the GIOSTAR website.

Also according to the website, the GIOSTAR team of scientists and clinicians have been involved in the development and utilization of stem cell based clinical protocols related to stem cell transplants for over 15 years.

The team includes international leaders in the field of adult stem cell, embryonic stem (ES) cells and Induced Pluripotent Stem (IPS) cells research and technologies. The GIOSTAR team is the first in demonstrating the significance of ES cell use for the development of therapies for several degenerative diseases related to tissue and organs. The publications of these therapies have been thoroughly investigated and documented by many noted journals of medicine. GIOSTAR is leading the most advanced research in the field of ES cells and IPS cells to develop new therapies for future clinical use.

Organization Aims to Set up Stem Cell Research Facilities Across Entire U.S.

Source :

Dr. Anand’s Editorial on Diabetes Type 1 & 2 in Journal of Stem Cell Research & Therapeutics

Dear Dr. Anand S Srivastava,



We are very pleased to inform you that your manuscript has successfully gone through all the required processes for publication. Certainly, your article deserves its place on the JSRT’s bookshelf, and we will do our best to share your endeavors with the world. That’s a promise.

Moreover I would like to have your profile in our journal, so I request you to send us your CV at the earliest possibility.

Await your contribution.

Best regards,

Grace Victoria

Diabetes Type 1 & 2 in Journal of Stem Cell Research & Therapeutics

 Diabetes: Stem Cells Offering Healthy Promises


Aditi Saraswat,1 Anand Srivastava2
1Henry Ford Medical Center, USA
2Global Institute of Stem Cell Therapy and Research, USA
Received: April 30, 2018 | Published: May 09, 2018

Correspondence: Anand Srivastava, Global Institute of Stem Cell Therapy and Research, 4660 La Jolla Village Drive, San Diego, CA, 92122, USA, Tel 8583 4424 92, Email 

Citation: Saraswat A, Srivastava A. Diabetes: stem cells offering healthy promises. J Stem Cell Res Ther. 2018;4(2):45‒46. DOI:10.15406/jsrt.2018.04.00113



Diabetes is a chronic lifelong disease and according to Diabetes Association of America, in 2015 itself approximately 30.3million Americans (9.4% of the population) have the disease. Unfortunately, almost one fourth (or approximately 7.2million) are unaware that they have it. An additional 84.1million people have pre-diabetes. With increasing prosperity, its prevalence has increased in almost all populations of the world and ranges from 5-15%. As it affects so big portion of the world population a long-lasting cure is urgently warranted. People with diabetes need to manage their disease in order to avoid related complications and maintain healthy social and economic interactions.

Diabetes affects individuals of all age groups and has been classified in two types. Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin. It is usually diagnosed in children and young adults, previously known as juvenile diabetes. Only 5% of people with diabetes have this form of the disease. On the other hand, type 2 diabetes (T2D) is the most common form of diabetes. In patients of T2D, the body does not use insulin properly mostly because of insulin resistance. Because of that, at first, pancreas compensates by making extra insulin. However, over time it isn’t able to keep up and can’t make enough insulin to keep your blood glucose at normal levels.

Diabetes affects every part of the body and causes complications related to heart, brain, kidney, circulatory system etc. Managing diabetes exerts a significant burden on the economy in general. During 2017, according to an estimate, diabetes-related care of people directly or indirectly could have costed around $327 billion.1 Though a number of medications are already in clinical use but none of them grant a long-term cure and all of them have some or other undesired side-effects.

 Since almost all pharmacological drugs, irrespective of the target molecule in the pathway involved in the manifestation of diabetes-related complications, have some side effects a safer and comparatively long last therapeutic alternative is desperately needed. To meet the continuous need for insulin, pancreatic transplants have been tried which turned out to be very cost-intensive and impractical because the donor pancreases have to be recovered from suitable cadavers and then transplanted.2 Logically, transplantation of a tissue from other individual comes up with so many concerns like compatibility of a graft in the new host and its survival as immune rejection is usually a valid concern most of the time. To circumvent all these concerns another alternative way of handling the problem was needed for a long time. Discovery of stem cells and related extensive research has offered a ray of hope to manage the problem efficiently with a sound possibility of a permanent cure.

Stem cells, depending on the source of their origin, are classified as embryonic or adult or induced. Embryonic stem cells are capable of differentiating in all cell types for a body while adult cells which have attained some tissue-specific differentiation, lose that ability slightly. Since a number of ethical issues crop up with use of embryonic cells, adult stem cells are next best type of cells to lean back on. Another favorable factor for using adult stem cells is that these can be isolated from tissues which are easy to extract from an individual like belly fat or bone marrow. Cells of these origins are classified as mesenchymal stem cells (MSCs). MSCs are known to promote the regeneration of pancreatic islet beta cells, protect endogenous pancreatic islet beta cells from apoptosis, and ameliorate insulin resistance of peripheral tissues by providing a supportive niche microenvironment driven by the secretion of paracrine factors or the deposition of extracellular matrix.3,4

In general, implantation of MSCs can alleviate T2D by a number of mechanisms. These cells, if implanted directly in the pancreas, thanks to their multipotential ability to differentiate in diverse types of cells of their immediate vicinity, can produce new insulin-producing cells. Investigators, in order to promote the chance of differentiation of cells in insulin-producing cells, have preprogrammed MSCs by culturing in serum-free high glucose media or neuron conditioned media before transplantation. Intravenous infusion of stem cell has been shown to regenerate beta cells of islets in rats5 also promote the survival during hypoxia and oxidant stress.6 In addition to these effects, infusion of stem cells has been shown to promote insulin sensitivity.7 Though the exact mechanism by which stem cell bring about increased insulin sensitivity is not deciphered, it could be because of stem-cell-mediated decrease in systemic inflammation as it is well established that insulin resistance is strongly correlated with chronic low-grade inflammation.

Encouraging findings in cases of diabetes treatments with stem cell therapies have led the clinicians to try implantation or infusion or both in the clinical set up also. On the clinical trial site of NIH, more than 150 trials at different stage have been listed. MSCs of diverse origins either were implanted directly in the pancreas8 or were infused in blood stream9 or both10 showed promising results up to 12 months of follow up. A couple of clinical parameters are often used to ascertain the effectiveness of a therapy in cases of diabetes. A decrease in Hb A1C is one of those parameters which were used by Estrada et al.11 and they reported a significant decrease.11 In another study, insulin need decreased or was abolished altogether.8 Similarly, implantation or infusion of MSCs has been shown to improve pancreatic function i.e. increased insulin production. Same time, increased insulin sensitivity is also attained by MSCs.

Just like other medical helps, stem cell therapy can have some undesirable effects, though the incidences are few and far between. Even those undesired effects, which happen after stem cell transplantation are very mild and easily manageable like mild to moderate fever or nausea or headache.

In conclusion, stem cell therapy does offer a long lasting therapeutic alternative for treating T2D. Same time it has to be kept in minds of both clinicians and patients that it is not a permanent cure. T2D is a metabolic syndrome which manifests after a long duration of unhealthy life style which needs to be addressed in order to lead a healthy life. Compared to all other available therapies, stem cell therapy can offer a lot longer period for individuals to develop a healthy life style which would help fend off re-occurrence of the disease.

Conflict of interest


Author declares that there is no conflict of interest.



  1. Enocrinology Advisor. Total Estimated Cost of Diagnosed Diabetes $327 Billion in 2017. Endocrinology Advisor. 2017.
  2. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230‒238.
  3. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076‒1084.
  4. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A. 2006;103(46):17438‒17443.
  5. Hao H, Liu J, Shen J, et al. Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys Res Commun. 2013;436(3):418‒423.
  6. Chandravanshi B, Bhonde RR. Shielding Engineered Islets With Mesenchymal Stem Cells Enhance Survival Under Hypoxia. J Cell Biochem. 2017;118(9):2672‒2683.
  7. Hughey CC, Ma L, James FD, et al. Mesenchymal stem cell transplantation for the infarcted heart: therapeutic potential for insulin resistance beyond the heart. Cardiovasc Diabetol. 2013;12:128.
  8. Bhansali A, Asokumar P, Walia R, et al. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant. 2014;23(9):1075‒1085.
  9. Jiang R, Han Z, Zhuo G, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5(1):94‒100.
  10. Liu X, Zheng P, Wang X, et al. A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther. 2014;5(2):57.
  11. Estrada EJ, Valacchi F, Nicora E, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant. 2008;17(12):1295‒1304.



Make An Enquiry

We are here to help you

WordPress Video Lightbox